Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07448038 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
A Phase 2 study, sponsored by Genentech.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
NCT07448038 is a Phase 2 study that is actively recruiting participants, run by Genentech. The registered enrollment target is 162 participants.
The verdict
NCT07448038, a Phase 2 study, is actively recruiting participants, sponsored by Genentech.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
Study Summary
The main purpose of the study is to evaluate the efficacy of selnoflast compared with placebo in participants with atherosclerosis, at high-risk for major adverse cardiovascular event (MACE), who are currently on standard-of-care (SOC) therapy.
Interventions
- DRUG Placebo
- DRUG Selnoflast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2026-06-05 |
| Est. Completion | 2028-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07448038
The ClinicalTrials.gov registry entry for NCT07448038 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07448038 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07448038 about?
NCT07448038 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events". The main purpose of the study is to evaluate the efficacy of selnoflast compared with placebo in participants with atherosclerosis, at high-risk for major adverse cardiovascular event (MACE), who are currently on standard-of-care (SOC) therapy.
What is the current status of trial NCT07448038?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2026-06-05. Estimated completion is 2028-02-28.
What interventions are being tested in trial NCT07448038?
The interventions under investigation include: Placebo (DRUG), Selnoflast (DRUG).
Who is sponsoring clinical trial NCT07448038?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.